All Recipharm facilities ready for EU serialisation, regardless of Brexit

15 Feb 2019

The CDMO invested EUR 35 million into its operations and launched a 3-year programme to provide a compliant serialisation solution for its customers.

Recipharm has announced that all 15 of its facilities outlined in its investment plan are now fully prepared for drug serialisation and have delivered serialised batches within Europe ahead of the 9 February deadline.

All Recipharm facilities ready for EU serialisation, regardless of Brexit

During the period 2016-2018, the CDMO invested EUR 35 million into its operations and launched a 3-year programme to provide a compliant serialisation solution for its customers, ahead of the introduction of the EU Falsified Medicines Directive (EU FMD) and the US Drug Supply Chain Security Act (DSCSA).

In addition, all of the facilities are connected to customers to allow them to report serial numbers. The facilities are located across Europe in France, Italy, Sweden, Spain, Germany, the UK and Portugal, as well as in India.

Staffan Widengren, Director Corporate Projects, said: “Recipharm has been very committed to meeting compliance deadlines, establishing a dedicated task force 3 years ago. A lot of time and effort has gone into our preparations so it’s rewarding to report that we are ready, especially ahead of the enforcement date.”

“Standardising our serialisation capabilities has enabled us to provide a seamless and flexible service to our customers, across multiple markets.”

After months of operational upheaval, the EU FMD regulation is now in effect. As CDMOs try to adhere to serialization requirements, how could Brexit affect the new regulations and how does Recipharm aims to handle products during this period?

"The uncertainty of Brexit lingers, pharmaceutical companies are still unsure as to how Brexit will affect the FMD requirements, said Staffan Widengren. He continued: "When the UK leaves the EU on Friday 29 March, it could be that the UK market does not require serialised products, whereas the EU will uphold the regulations. This means that when drug products are transferred from the UK to the EU market, they will still need to comply with FMD requirements.

"Ultimately, the operational approach of pharmaceutical firms will depend on whether the UK remains part of the current European Medicines Verification Organization (EMVO) or European Medicines Verification Systems (EMVS), like many of the European Election Studies (EES) countries, or if they decide to adopt a new and separate system.

"In the meantime, Recipharm will handle all products as EU products and report serial numbers to the EU Hub and national systems. It is imperative that pharma companies not yet compliant with the new regulation, outsource their serialisation requirements and co-operate with their partners as this will ultimately help to protect the safety of patients."

Read More

Related news

GSK opens new continuous manufacturing facilities in Singapore

GSK opens new continuous manufacturing facilities in Singapore

11 Jul 2019

Opening of continuous manufacturing facilities and expansion of production building will boost capabilities to accelerate the supply of new breakthrough medicines to patients globally.

Read more 
Catalent extends global commercial spray drying capabilities in Europe

Catalent extends global commercial spray drying capabilities in Europe

9 Jul 2019

Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.

Read more 
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more 
Lessons learned from early EU FMD adopters

Lessons learned from early EU FMD adopters

13 May 2019

Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.

Read more 
Brexit's trick or treat on patient safety

Brexit's trick or treat on patient safety

29 Apr 2019

Despite a delayed Brexit, unpredictability adds further complications to the EU FMD regulation.

Read more 
Surge of Indian biosimilars market forecast in 2019

Surge of Indian biosimilars market forecast in 2019

22 Apr 2019

India predicted to be one of the world’s ‘fastest growing bio’ hubs in 2019, fuelled by new biosimilars production.

Read more 
RAPS on delayed Brexit

RAPS on delayed Brexit

26 Mar 2019

The post-Brexit regulatory environment continues to weigh heavily on the minds of regulatory professionals.

Read more 
Sizeable growth potential for global drug delivery and packaging in 2019

Sizeable growth potential for global drug delivery and packaging in 2019

19 Mar 2019

Patient-centricity, eco-friendly and smart packaging trends marked as the biggest growth drivers and innovations in 2019.

Read more 
'Tamper-evident' benefits are evident

'Tamper-evident' benefits are evident

28 Feb 2019

2019 will mark Uniplast's debut at this year's edition of CPhI Worlwide in Frankfurt, where it will showcase its expertise in plastic packaging.

Read more 
Brexit - the EU FMD's painful problem

Brexit - the EU FMD's painful problem

7 Feb 2019

Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.

Read more